NCT03437590View on ClinicalTrials.gov

A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

October 19, 2018

Study Completion Date

October 19, 2018

Conditions
Healthy
Interventions
DRUG

JNJ-55308942

JNJ-55308942 will be administered as oral solution.

DRUG

[18F]-JNJ-64413739

\[18F\]-JNJ-64413739 fluid for injection administered intravenously.

Trial Locations (1)

3000

UZ Leuven Gasthuisberg, Leuven

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY